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Abstract
Background: Requirements for frequent dispensing of antiretroviral therapy (ART) place demands on health systems
and can lead to suboptimal adherence and disengagement in care for patients due to the time and cost of frequent
clinic visits. Rigorous data are needed to define optimal ART dispensing strategies and to evaluate the impact of a longer
medication supply on retention and virologic suppression and determine whether this strategy lowers costs for both the
patient and the health system. To date, no randomized studies have tested the benefits of 6-month dispensing of ART
compared to 3-month and standard of care approaches.
Methods: This study will be an unblinded cluster-randomized, matched controlled trial conducted among 8200 stable,
HIV-infected individuals age 18 years and older on ART in Malawi and Zambia, to compare three ART dispensing
intervals on the outcomes of retention in care (primary outcome), virologic suppression, and cost-effectiveness.
Thirty clusters will be matched according to country, facility type, and ART cohort size and randomized to one of
three study arms: standard of care, 3-month dispensing, and 6-month dispensing. Study participants will be followed, and
outcomes will be measured at 12, 24, and 36 months. A subset of participants (n = 240) and providers (n = 180) will also
participate in qualitative interviews to evaluate feasibility and acceptability of different ART dispensing intervals.
Discussion: This study will be the first to compare 6-month and 3-month ART dispensing intervals for stable, HIV-infected
individuals in Malawi and Zambia. We focus on outcomes relevant to country programs, including retention, virologic
suppression, and cost-effectiveness. Results from the study will help resource-limited health systems better understand
the full scope of outcomes resulting from various ART dispensing intervals and help to inform health policy decisions.
Trial Registration: ClinicalTrials.gov, NCT03101592. Registered on 18 March 2017.
Pan African Clinical Trials, PACTR201706002336105. Registered on 2 June 2017.
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Background
The 2015, the World Health Organization (WHO),
the Joint United Nations Program on HIV/AIDS
(UNAIDS), and the U.S. President’s Emergency Plan
for AIDS Research (PEPFAR) all announced their sup-
port for global HIV control targets known as “90-90-
90” [1, 2]. The goals of 90-90-90 are to identify 90%
of people living with HIV, initiate 90% of HIV-
diagnosed individuals on ART, and achieve viral sup-
pression in 90% of those on ART. Modeling has indi-
cated that achieving the 90-90-90 targets will require
most low-income and middle-income countries to in-
crease sharply the number of patients successfully
retained on lifelong ART, with major implications for
the resource requirements and costs of national treat-
ment programs, and will heighten the challenge of
maintaining program quality and improving patient
outcomes as access expands.
Barriers to achieving the “third 90”—long-term viral
suppression—include sub-optimal adherence and reten-
tion in care. For patients in sub-Saharan Africa, reasons
for these poor outcomes have included the requirement
for frequent clinic visits to receive medication refills,
long wait times in ART clinics, high costs for travel to
clinics, missed wages, and life events that lead to missed
clinic visits [3–6]. Data from Zambia, a country with
lower-middle income and high HIV prevalence in south-
ern Africa, for example, suggest that requirements for
monthly dispensing and/or guidelines that require mul-
tiple separate visits for refills and clinician evaluation
impose a large burden on individuals living with HIV,
which can in turn lead to treatment interruptions or
complete disengagement from care [7].
One potential solution to this problem is to in-
crease dispensing intervals to as long as 6 months to
reduce patients’ visits to the clinic. An observational
analysis of 130,000 patients in Zambia showed that
patients on a 6-monthly appointment schedule were
less likely than those on a monthly schedule to have
gaps in medication refills (adjusted odds ratio (aOR)
0.50, 95% confidence interval (CI) 0.43–0.57) or be
lost to follow up (aOR 0.48, 95% CI 0.40–0.59) [8].
Extension of refill intervals has been employed in
many high-resource settings, including the USA, with
supply provided up to every 6 months for stable pa-
tients [9, 10]. Potential benefits of multi-month dis-
pensing may include improved adherence to ART,
improved retention in care, and decongestion of
clinics, which allows staff to focus on the sick, allows
the clinic to initiate more new patients on ART, im-
proves operational efficiency at clinics, and reduces
costs of providing and obtaining ART.
Although the evidence from Zambia cited above is
promising, it reflects the fact that longer dispensing
intervals were almost certainly assigned to the patients
with the best adherence records, and thus cannot tell us
how multi-month dispensing affects outcomes. A review
of the literature reveals no randomized studies of ART
dispensing intervals in resource-limited settings and no
cost estimates from real-world settings. Rigorous data
are needed to define optimal dispensing strategies and to
determine whether longer drug supply intervals result in
improved outcomes and/or lower costs for both the pa-
tient and the health system.
The main objective of the INTERVAL study, a PEPFAR/
US Agency for International Development (USAID)-sup-
ported, multi-site cluster-randomized trial, is to compare
standard of care to 3-month and 6-month ART dispens-
ing. The primary outcomes to be studied are retention in
care at 12, 24, and 36 months. We will also evaluate sec-
ondary outcomes of virologic suppression and cost-
effectiveness at these same time points. INTERVAL will
contribute to the limited body of knowledge on multi-
month dispensing of ART in resource-limited settings and
may be used to better define best practices for cost-
effective ART programs in Malawi, Zambia, and similar
settings.
Methods/design
INTERVAL will be a pragmatic, cluster-randomized, non-
blinded, non-inferiority trial conducted at 30 health facil-
ities in Malawi and Zambia. It will compare three ART
dispensing strategies for stable patients – (1) standard of
care, (2) 3-month ART dispensing, and (3) 6-month ART
dispensing – on retention in care in Malawi and Zambia.
The study protocol was developed using the SPIRIT
(Standard Protocol Items: Recommendations for Inter-
ventional Trials) Checklist (see Additional file 1) and
adheres to the SPIRIT recommendations. The protocol
has been approved by the institutional review board of
the University of California, Los Angeles (UCLA), the
National Health Sciences Research Council (NHSRC) in
Malawi, the Zambia Excellence in Research Ethics and
Science (ERES) Converge, the Zambia National Health
Research Board (ZNHRB), and the Zambia Medicines
Regulatory Authority (ZAMRA). The trial is registered
with ClinicalTrials.gov as NCT03101592.
Intervention
This study will compare standard of care to two alterna-
tive dispensing strategies. Under standard of care, ART
dispensing intervals are based on provider opinion.
Malawi and Zambia ART guidelines recommend 3-
month dispensing for stable patients, but adherence to
guidelines is variable and dispensing may vary due to
provider and/or patient preference or medication avail-
ability. Participants in the 3-month dispensing study arm
will receive a 90-day supply of ART and will have routine
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clinic visits every 90 days. Participants in the 6-month
dispensing study arm will receive a 180-day supply of
ART and will have routine clinic visits every 180 days.
For all arms, other HIV services will be standard of care
and supplies of co-trimoxazole (CPT) and isoniazid
(IPT) will also be provided based on the assigned ART
dispensing interval and country-specific guidelines about
use of these therapies as part of routine HIV care.
Pharmacy support will be provided as part of the study,
to ensure medication stock outs do not occur at study
sites and that study sites do not take drug stocks away
from non-study facilities. The trial is being conducted in
close collaboration with the Ministries of Health in
Malawi and Zambia and USAID, with support from the
Supply Chain Management Systems (SCMS). Participants
in the 6-month arm will be offered generic plastic bags to
assist with carrying the large supply of medications. Par-
ticipants will be given information about “ideal” basic stor-
age conditions for medications, particularly in regard to
temperature and avoidance of storage in direct sunlight.
Participants who provide written informed consent will be
willing to participate in any of the study arms; however,
those in the 6-month arm may request a reduction in refill
duration at any point during follow up. The proportion of
individuals changing from 6-month ART dispensing to
shorter intervals and reasons for changing will be captured
during follow up.
To measure the primary outcome of retention, data
will be abstracted from participants’ medical records. In
Malawi and Zambia, default from care is defined as be-
ing out of ART for more than 60 days, and this defin-
ition will be used for the endpoint of retention (<60 days
without ART at each time point).
Secondary study outcomes include virologic sup-
pression, cost-effectiveness, and feasibility and accept-
ability to patients and to providers and will be
measured at 12, 24, and 36 months. Viral load data
will be obtained from medical records based on any
available data recorded during the prior year. Cost-
effectiveness will be analyzed from both patient and
health system perspectives by surveying participants
at enrollment about time and costs associated with
each clinic visit and by creating inventories of all
resources and costs to the facility and health system
for each patient visit. Feasibility and acceptability will
be measured by conducting qualitative in-depth inter-
views with a subset of 240 participants (120 per
country) and 180 providers (90 per country) evenly
balanced among the three study arms. A flowchart of
the study is provided in Fig. 1. Our main hypothesis
is that 6-month ART dispensing will be non-inferior
to 3-month intervals for retention and virologic sup-
pression, but that 6-month intervals will be cost-
effective compared to 3-month intervals.
Study sites
The study will be conducted at 30 clusters in Malawi and
Zambia. A cluster is defined as a hospital or health center
that serves as an outpatient ART site. All clusters will
either be government or mission facilities that provide free
HIV care. Clusters will be selected based on ART cohort
size and ability to enroll at least 271 participants, ability to
perform viral load testing as part of routine care, com-
pleteness of medical records, and willingness to participate
in the study. Sites in Malawi will be selected from the
Central and Southern regions, and sites in Zambia will be
selected from Central and Copperbelt Provinces. Sites par-
ticipating in ongoing research that influences the fre-
quency or location in which patients receive ART will be
excluded, as will those that have active research underway
on adherence and retention.
Blinding and allocation
Random assignment of matched clusters will be deter-
mined by computer. Clusters will be matched based on
available information that could potentially predict out-
comes, including ART cohort size and region. Matched
clusters will then be randomly allocated with one receiv-
ing the 3-month intervention, one the 6-month inter-
vention, and one the control condition. Allocation will
be completed by the study analyst. Clusters will then be
informed of the allocation. No attempt will be made to
blind the sites or patients to their allocated group, as
both providers and patients will be aware of the amount
of medication dispensed and the timing between
appointments.
Study population and sample size
HIV-infected individuals age 18 years or older who are
considered stable on ART will be enrolled in the study.
The definition of “stable on ART” and other inclusion
and exclusion criteria are summarized in Table 1. Since
there is no universally accepted definition of stability,
criteria were developed for the study based on the expert
opinion of infectious diseases specialists. As this is a
cluster-randomized trial, study participants will receive
the dispensing strategy that was randomly assigned to
the cluster (health facility) at which they receive their
HIV care.
Sample size
Our study sample size was estimated for a cluster-
randomized non-inferiority trial. With 30 clusters avail-
able for randomization, we estimated the sample size as-
suming a fixed number of clusters (k), an equal number
of clusters per arm, and an equal number of subjects per
cluster. Using a one-sided Z test (unpooled) with a sig-
nificance level of 0.05, we estimated that about 5% of
subjects would fail to be retained in care in the
Hoffman et al. Trials  (2017) 18:476 Page 3 of 10
standard of care arm and 7.5% to be non-inferior in the
3-month or 6-month study arms. Assuming power of
90% and an intracluster correlation coefficient (ICC) of
0.004 [11], we will need to enroll 271 subjects per cluster
for a total of 2710 subjects per arm and 8130 total
individuals.
Study procedures and data collection
The study procedures and data collection methods are de-
scribed in detail below. A summary of the study visits and
evaluations is outlined in the SPIRIT Figure (Fig. 2) below.
Eligibility screening
Patients will be provided general information about the
study in ART clinic waiting areas and recruited by a
study staff representative. Interested patients will be
taken to a private space with a study staff representative
to learn about the study, provide oral consent, undergo
anonymous screening procedures, and, if eligible,
provide written informed consent. A recent viral load
test (within 6 months of the entry visit date) is required
to determine eligibility; however, we anticipate many
participants will not have a recent viral load result avail-
able at the time of screening. For participants who do
not have a viral load documented, a sample will be col-
lected after written informed consent is obtained, but
the participant will not be enrolled in the study until the
test results have been received. Patients who have a viral
load sample drawn for study eligibility will receive test
results during their next routine visit and will repeat the
screening survey at that visit to ensure there have been
no changes in eligibility criteria over the interim period.
Entry visit data collection
All patient baseline data will be collected in the entry
visit, which may come immediately after screening for
eligible patients, or may take place at the next visit when
a viral load result is available. Two types of data will be
Fig. 1 Flowchart of study protocol. *See Table 1. ART antiretroviral therapy
Hoffman et al. Trials  (2017) 18:476 Page 4 of 10
collected at the entry visit. First, the participant’s medical
record will be reviewed to collect clinical history, includ-
ing date of HIV diagnosis, date of ART initiation, use of
CPT and/or IPT, and history of ART clinic visits and
ART dispensing intervals in the prior 12 months. The
second type of data will come from an interview with
the patient. In the interview, the study interviewer will
obtain sociodemographic information about the partici-
pant, including gender, highest level of education, house-
hold composition, employment status, HIV disclosure
status, and travel and opportunity costs related to the
participant’s ART clinic visits. After completion of the
entry visit data collection, the participant will complete
her or his routine clinic visit with site providers and re-
ceive ART dispensing as per the site randomization. If
CPT and/or IPT dispensing is standard of care for the
facility, CPT and/or IPT will also be provided as per the
randomized dispensing interval.
Follow-up data collection
Retention and virologic suppression will be assessed 12,
24, and 36 months after the entry visit date. At each of
these time points, data from participants’ medical re-
cords will be collected by study staff. Data will include
number, timing, and reason for clinic visits, retention in
care (and if not retained, reason), possession of ART
based on number of pills dispensed at each visit, posses-
sion of CPT and/or IPT based on number of pills dis-
pensed at each visit, and viral load. Study staff will allow
up to 60 days after a time point has been reached before
medical record review, allowing for participants to meet
the protocol-defined definition of default. For partici-
pants who default, facility standard of care procedures
for tracing may be used, but the study will not make
contact with the participant for the purposes of facilitat-
ing return to care.
Qualitative data collection
To help understand patients’ and providers’ perceived feasi-
bility and acceptability of the dispensing intervals offered in
the study, qualitative, semi-structured, in-depth interviews
will be conducted at the study sites for both patients and
providers after the 12-month primary endpoint has been
reached. For study participants, a subset (up to 40 from each
arm in Malawi and another 40 from each arm in Zambia, or
a total of up to 240 individuals) will be randomly selected to
participate in an individual, in-depth, qualitative interview.
Participants will only be contacted for an interview if they
provide informed consent for future contact at the time of
initial written informed consent. Those who agree to an
interview will return to the clinic for this step and will be re-
imbursed transport costs for this study visit. The interview
will be conducted in a private room at the clinic in a local
language and will last approximately 1 hour. Participants will
be asked about their experiences receiving their assigned
dispensing interval, including challenges in transporting
medications from clinic, challenges in storing medications at
home, pressure to sell or give ART supply to others, clinic
usage outside of ART refills, and perceived financial chal-
lenges that result from clinic visits.
There is a possibility that the interviews may influence
participants’ future outcomes in the study, particularly
retention in care. Patients may change their behavior as
a result of more intensive contact with study staff, be-
cause of being reimbursed for a study visit, or as a result
of information discussed in the interview. The total
number of individuals participating in interviews is less
than 3% of the total study population, and these individ-
uals will be excluded from outcome analyses after the
first year.
We will also collect qualitative data from a subset of
providers (n = 30) drawn from lists provided by the study
sites from each of the three study arms in each country
(total n = 180). These interviews will be performed after
50% of the facility’s study participants have reached the
12-month endpoint. For providers who agree to
Table 1 Study inclusion and exclusion criteria
Inclusion criteria
• Confirmed HIV-1 infection based on country standard of care for
testing algorithm
• Stable on ART, defined as:
− on ART for at least 6 months
− on a first-line ART regimen as defined by country-specific guidelines
(efavirenz, tenofovir, and emtricitabine or lamivudine)
− no drug toxicity/tolerability issues within the prior 6 months
− no period of more than 1 month without medication possession
within the last 6 months
− no active opportunistic infection (OI) suspected (including
tuberculosis (TB)) and not treated for an OI within the last
30 days
− undetectable viral load (as defined by country guidelines) within
the last 6 months:
▪ Malawi: less than 1000 copies/mL
▪ Zambia: less than 20 copies/mL
• Willing and able to provide written informed consent
• Planning to receive HIV care from the same facility for at least 1 year
Exclusion criteria
• Co-morbid condition(s) for which the individual is treated at the ART
clinic (hypertension, diabetes mellitus, chronic lung disease, etc.)
• Pregnant or breastfeeding, or if not breastfeeding, less than
6 months postpartum
• Already receiving care within a differentiated model in which care is
received as a group or in a community, such as a community-based
adherence group or adherence club
• Enrolled in any other research studies that would influence ART
adherence, retention, or dispensing interval
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participate, study staff will complete an anonymous
screening survey to determine eligibility to participate in
the interview. If eligible, providers will be asked for writ-
ten informed consent. The interviews will be conducted
in English in a private space at the facility. Questions
will focus on provider perceptions of challenges faced by
patients in transporting or storing medications; percep-
tions of the degree to which patients lose, sell, or give
away ART; issues related to medication stock and stor-
age within their facility; and perceptions about the effect
of ART dispensing interval on clinic efficiency and
health system costs.
Cost-effectiveness data collection
To estimate the provider costs of the different dispensing
intervals per patient treated, we will create an inventory of
all resources used to achieve the observed study outcomes
from study enrollment to the 12-month, 24-month, and
36-month time points, including ART medications, non-
ART medications, laboratory tests, outpatient clinic visits,
other clinic services provided, inpatient care visits, fixed
costs of patient care, and depreciated investment costs of
establishing capacity for multi-month dispensing (e.g.,
medication storage capacity, pharmacy infrastructure, staff
training, etc.). Data will be abstracted from patients’ med-
ical records and the site’s performance reports (e.g. for pa-
tient volumes served) and finance and procurement
records (for unit costs). Where necessary, cost data will
also be obtained from national sources (e.g. Ministry of
Health salary scales), commercial price lists, other cost-
related studies underway in the INTERVAL countries, and
published sources.
Fig. 2 SPIRIT Figure. *Default defined as out of antiretroviral therapy (ART) for more than 60 days; &Zambia only; ^Malawi only; CPT: co-trimoxazole
prophylaxis therapy; IPT: isoniazid preventive therapy
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Fixed or indirect costs at the facility level include
space, utilities, shared staff such as data clerks or man-
agers, and other resources that do not vary directly with
patient numbers, and will be allocated to study patients
based on the proportion of total facility resources uti-
lized for ART clinic visits. For example, if 10% of a
clinic’s total number of visits per month is for ART pa-
tients, then 10% of overall clinic fixed costs will be allo-
cated to ART and divided by the total number of ART
patients to estimate a fixed cost for each clinic. If data
on monthly clinic visits are not available, fixed costs will
be allocated on the basis of space utilization. Data on
costs incurred by patients for each of the arms will be
collected through the entry visit survey, as described
above. We will not estimate costs incurred above the
level of individual facilities, such as those incurred by
the government for overall HIV program management.
Data safety and monitoring plan
The first data analysis will be performed when 50% of
participants have reached 12 months of follow up. The
study will be stopped early if we find a difference (at 12
or 24 months) between 3-month versus 6-month dis-
pensing with a p value <0.01. Operational futility may be
considered if the observed accrual patterns are exceed-
ingly different than planned, and the protocol team has
had a chance to address the shortcomings of accrual.
Data analysis
Primary outcome
Our primary outcome, which is the basis for our sample
size estimates and primary analysis, is retention in care
at 12 months after study enrollment. Data analyses will
begin with descriptive measures about the study popula-
tion stratified by treatment arm and by facility and
presented as medians and interquartile ranges for con-
tinuous measures and proportions for categorical vari-
ables. These measures will be used to look for large
variations by facility and for imbalances between
study arms.
We will perform an intention-to-treat analysis for the
primary outcome of retention. Our analysis will use a
log-linear generalized estimating equation to estimate
the risk ratios and associated 95% confidence interval
for the effect of each intervention arm compared to
standard of care. We will specify facility-level clustering
to account for the study design and estimate robust
standard errors using an unstructured correlation
matrix. Should we identify any baseline imbalances be-
tween study arms, we will adjust for these in our multi-
variable model and report adjusted risk ratios and
corresponding 95% confidence intervals.
Secondary outcomes
Our study has not been powered to look at secondary
aims, but we expect to have enough power to explore
differences in secondary endpoints. The analytic
methods for the secondary outcome of virologic sup-
pression will be identical to those described above for
the primary outcome of retention. For qualitative sec-
ondary outcomes of patient and provider feasibility and
acceptability of dispensing intervals, interviews will be
transcribed by trained personnel. Interviews will be ana-
lyzed in Atlas.ti v.6.2 using thematic analysis. Two inves-
tigators will code the first five to ten interviews by
themes and compare coding to reach a consensus. A
codebook will be developed, and two individuals will in-
dependently code all transcripts and compare codes to
reach a consensus. For each theme, we will describe the
range, central tendency, and context in which each
theme emerges. This process will be done separately for
participants and providers.
Cost-effectiveness will be assessed as the average cost
per patient achieving the primary outcome in each arm.
Cost will be estimated using micro-costing methods de-
veloped by the investigators and widely published [12–
14]. Costs will be reported as means with 95% confi-
dence intervals and medians with IQRs. Using the aver-
age cost per patient, we will then estimate the cost per
outcome achieved in each arm. We will compare average
cost/patient retained in care across the three study arms,
initially at 12 months and again at 24 and 36 months.
The annual cost of providing ART under each of the
three strategies evaluated (independent of outcomes) for
the overall HIV program budget in each country will be
estimated by combining the cost per patient treated
under each strategy, study data on the proportions of all
ART patients at study clinics who are eligible for each
dispensing interval, and up-to-date, published or re-
ported estimates of total numbers of patients on ART in
each country.
To estimate the costs to patients of obtaining ART, we
will use baseline patient interview data to calculate an
average cost per clinic visit, including transport fares,
food and accommodation while away from home, lost
wages, and substitute labor. For each participant, the
number of clinic visits made per 12-month period for
any HIV-related reason will then be multiplied by the
cost per visit. We will estimate and compare the average
cost per patient of obtaining care in each study arm.
Finally, we will explore clinic resource allocation to de-
termine the effects of the dispensing interval on patients’
access to care. We will use two proxy measures to
analyze access. First, we will estimate and compare the
average waiting time and/or total time in clinic among
patients seeking HIV care in each arm of the study. Sec-
ond, we will use aggregate, clinic-level data to ascertain
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whether the quantity or mix of services provided by each
study site changes between the last month before the
start of the study and the first month of year 2 of the
study. While neither of these measures is a perfect indi-
cator of access, both will provide some indication of the
availability of both HIV care and care for non-HIV
conditions.
Discussion
To date, no randomized studies have been conducted to
evaluate the benefits and challenges associated with longer
ART dispensing intervals in resource-limited settings. This
study will be the first to compare standard of care, 3-
month, and 6-month ART dispensing intervals for stable,
HIV-infected individuals in Malawi and Zambia. We focus
on outcomes that are relevant to national HIV programs
and that could result in widespread policy changes. Results
from the study will help limited-resource health systems
better understand the full scope of outcomes resulting from
various ART dispensing intervals and help to inform health
policy decisions. Our study is innovative in that it includes
qualitative data collection from patients and providers.
These data can help to address questions about moving to
longer dispensing intervals, including around patient expe-
riences transporting a large supply of medications (6 months
of ART, CPT, and/or IPT), patient challenges with storage
of these large supplies, particularly for those who have not
disclosed to other members living in the same household,
and concerns that patients given a large supply of ART
may be inclined to sell medications for income or provide
them to friends or family. We will also estimate both total
costs of implementation and cost-effectiveness. Cost sav-
ings are widely anticipated from adopting longer follow-up
intervals, but such savings have yet to be demonstrated or
quantified in real-world settings, making the economic
evaluation essential for resource allocation decisions.
This study has several limitations. Apart from the
entry viral load, the study will not perform follow-up
viral load testing. Therefore, results for the secondary
outcome of viral load will be limited to those tests per-
formed within the context of routine care. In Zambia,
viral load monitoring is performed annually, and in
Malawi, monitoring occurs every 2 years. We anticipate
that viral load results may be missing from a large num-
ber of participants as these programs are both early in
their viral load scale-up efforts. Because of these con-
cerns, viral suppression is a secondary outcome. Our
definition of a “stable” ART patient was developed in
conjunction with HIV experts and takes into consider-
ation published literature on this topic [2, 15–17]. Our
results may not be generalizable in settings that use a
different definition of stable. There may be a subset of
unstable ART patients who struggle with retention be-
cause of circumstances that prevent frequent follow-up
to an ART facility (living remotely, difficult work sched-
ule, school or work outside of the country). These indi-
viduals could benefit from a 6-month dispensing
interval, but they will not be included in our study, and
their outcomes will not be captured.
Participant blinding will not be used in the trial as
there is no way to blind providers or patients to their
assigned group. Lack of blinding could potentially influ-
ence the study results as participants who are motivated
to have a longer drug supply could transfer to a study fa-
cility with 6-month dispensing. Additionally, regardless
of arm, participants may be more likely to be retained if
they know they are being followed as part of a study.
We have attempted to reduce bias by limiting inter-
action with study participants to the screening and entry
visits, which will both coincide with routine ART visits.
All subsequent data will be obtained from medical rec-
ord review with the exception of a small subset of partic-
ipants (n = 240 across both countries) who will be asked
to complete in-depth interviews at the end of the first
year. These limitations will be noted in study findings
when they are presented.
It is possible that Malawi and Zambia will revise their
HIV treatment guidelines during study follow up, in-
cluding extending dispensing intervals to 4 months or
longer. In Malawi, IPT rollout in high-burden TB dis-
tricts is anticipated during the first year of the study,
and this will result in patients returning to clinic for
extra visits to adhere to the IPT monitoring schedule
(monthly for the first 3 months of treatment). These na-
tional guideline changes will be captured at the level of
individual participant data and accounted for in our ana-
lyses, but they may influence our ability to measure
intended study outcomes. Finally, the study will be
working alongside Ministry of Health in both Malawi
and Zambia to ensure that sites randomized to 6 months
will have adequate supplies of ART, CPT, and IPT.
Should countries adopt 6-month dispensing, this high
level of support would be unlikely to be available at all
sites, resulting in potential challenges with procurement,
supply chain, and/or storage.
Despite these limitations, this study will be the first
randomized effort to measure multi-month ART dis-
pensing intervals on the outcomes of retention, virologic
suppression, and cost-effectiveness. If 6-month dispens-
ing intervals are proven to be non-inferior and cost-
effective, the results may help to inform ART dispensing
standard of care guidelines in Malawi, Zambia, and other
limited-resource health systems.
Trial status
This manuscript was developed using study protocol
version 2.4, 22 June 2017, for “The INTERVAL Study:
Varying Intervals of ART Dispensing to Improve
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Outcomes in HIV”. Recruitment and enrollment began
31 May 2017. Enrollment is expected to be completed
by 30 November 2017.
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